Improved systemic inflammatory status could represent a significant cofactor in reducing the risk of NAFLD progression and HCC development, as well as a crucial determinant of the cardiovascular protection exerted by GLP-1 RAs [139]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.